Speciality Medicines IPO: SME stock to list today. Check price band, other details

Synopsis

Speciality Medicines shares debut on the BSE SME platform today. The company's IPO, a fresh issue, sought to raise approximately Rs 29 crore. The price band was set between Rs 117 and Rs 124 per share. Proceeds will fund an R&D centre, international registrations, and marketing. The company operates in speciality pharmaceuticals, with a global presence.

Speciality Medicines shares will list today on the BSE SME platform.

The SME IPO, which was entirely a fresh issue, aimed to raise around Rs 29 crore.

The company fixed the price band at Rs 117–124 per share, with shares set to list on the BSE SME platform on March 30.

The IPO comprised a fresh issue of 23.5 lakh shares, with around 22 lakh shares being offered to the public after accounting for the market maker portion. Aikyam Capital will act as the market maker, while Unistone Capital is the book-running lead manager.

Retail investors could apply for a minimum of 2,000 shares, translating into an investment of Rs 2.48 lakh at the upper price band. The issue allocation structure mandated at least 49% each for retail and non-institutional investors, with QIB participation capped at 2%.

About Speciality Medicines

Incorporated in 2021, Speciality Medicines operates in the niche segment of speciality pharmaceuticals, focusing on marketing and distribution of high-value formulations used in chronic and complex conditions. Its product portfolio spans multiple dosage formats including injectables, inhalers, ophthalmic solutions and oral formulations.

The company follows a dual business model comprising contract manufacturing for international markets and distribution of sourced speciality pharma products. It has built a global footprint, with presence across more than 35 countries and operations spanning over 20 states in India.

As of February 2026, the company had seven products registered overseas, while 54 products were under registration across multiple international markets, indicating ongoing expansion efforts.

Speciality Medicines financials

Financially, the company has demonstrated steady growth. For the financial year ended March 2025, it reported revenue of Rs 58.54 crore and profit after tax of Rs 8.61 crore. For the period ended October 2025, revenue stood at Rs 36.93 crore with profit at Rs 6.06 crore.

The proceeds from the IPO will be used primarily to set up a new R&D centre in Gujarat, fund international product registrations, support marketing initiatives and meet working capital requirements.

While the business offers exposure to a niche and scalable pharma segment, the flat GMP suggests that investors may adopt a selective approach, tracking subscription demand and institutional participation more closely during the bidding period.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)

...moreless

...moreless